Why Bioscience Will Increasingly Call The Plays

By Fred Hassan & Göran Ando

Few catalytic events have moved the cross-industry S&P 500 index upward more than the biopharma news that started in November 2020.

That’s when we found out about the stunning development speed and the 90%+ efficacy rates of the two lead mRNA vaccines from Pfizer-BioNTech and Moderna. These rates were well above the FDA prespecified threshold of 50%. Since that time, all 11 S&P sectors in the economy have moved up, sparked by that one sector — healthcare. The torque in the snap-back of the U.S. economy from the sharp recession in 2020 is truly unprecedented.